Systemic Relapse in a Young Adult Patient with Primary CNS Diffuse Large B-Cell Lymphoma

Table 2

Agents with activity in R/R PCNSL.

Author	Agents	Study type	of patients	ORR (PR + CR)	Median PFS, mo	Median OS, mo
Fischer et al. [35]	Topotecan	Prospective	27	9/27 (33%)	2	8.4
Voloschin et al. [36]	Topotecan	Prospective	15	6/15 (40%)	2 (60 d)	32.7
Reni et al. [37]	Temozolomide	Prospective	36	11/36 (31%)	2.8	3.9
Soussain et al. [38]	CYVE + SCT	Prospective	43	20/40 (50%)	11.6	18.3
Batchelor et al. [39]	Ritux	Prospective	11	4/11 (36%)	1.9 (57 d)	20.9
Raizer et al. [40]	Pemetrexed	Prospective	11	6/11 (55%)	5.7	10.1
Dietrich et al. [41]	Pemetrexed	Prospective	14	8/14 (57%)	4.2	44.5+
Rubenstein et al. [42]	IT Ritux + IT MTX	Prospective	14 (6 PCNSL)	6/14 (43%)	1.2	NR
Nayak et al. [43]	Ritux + temozolomide+pred	Prospective	16	5/14 (36%)	1.6 (7 wk)	NR
Korfel et al. [44]	Temsirolimus	Prospective	37	20/37 (54%)	2.1	3.7
Grommes et al. [45]	Ibrutinib	Prospective	20 (13 PCNSL)	10/13 (77%)	4.6	15 (PCNSL)
Grommes et al. [46]	Ibrutinib + HD-MTX + Ritux	Prospective	15	12/14 (80%)	9.2	NR
Roschewski et al. [47]	TEDDi-R : ibrutinib + anthracycline	Prospective	18	9/13 (69%)	15.2	NR
Rubenstein et al. [48]	Lenalidomide	Prospective	14	9/14 (64%)	6	NR
Ghesquieres et al. [49]	Revri : Lenalidomide + Ritux	Prospective	50	16/50 (32%)	7.5	14.7
Tun et al. [50]	Pomalidomide + dexamethasone	Prospective	29	12/25 (48%)	5.3	NR
Fox et al. [51]	Tier : Thiotepa + ifos + eto + Ritux	Prospective	27	14/27 (52%)	3	5
Kasenda et al. [52]	HDAra-C + Thiotepa + Ritux + SCT	Prospective	39	28/39 (72%)	12.4	NR
Gavrilenko et al. [53]	Nivolumab	Prospective	9 (8 PCNSL)	7/9 (78%)	12	12
Siddiqi et al. [54]	CD19 CAR-T-cell therapy	Prospective	7 (3 PCNSL)	4/7 (57%)	NR	NR
Li et al. [55]	CD19/CD22 CAR-T-cell therapy	Prospective	5 (1 PCNSL)	5/5 (100%)	3	NR
Tu et al. [29]	CD19/CD70 CAR-T-cell therapy	Case study	1	1/1 (100%)	>17	>17
Siddiqi et al. [56]	CD19 CAR-T-cell therapy	Case series	5	3/5 (60%)	NR	NR

ORR, overall response rate; CR, complete response; PR, partial response; PFS, progression free survival; OS, overall survival; NR, not reported; IT, intrathecal; pred, prednisone; HDAra-C, high-dose cytarabine; CYVE, cytarabine + etoposide; SCT, stem cell transplant; HD-MTX, high-dose methotrexate; Ritux, rituximab; ifos, ifosfamide; eto, etoposide; CAR, chimeric antigen receptor.